Table 1. Patients` characteristics.
| No. | Sex | Age | Myeloma type | Cytogenetics | Disease duration | Previous treatment | Previous auto-Tx | Previous allo-Tx |
|---|---|---|---|---|---|---|---|---|
| 1 | m | 60 | IgA λ | high risk | 7.6 | CTx, RTx | yes | yes |
| 2 | m | 59 | IgA λ | n/a | 7.9 | CTx, RTx | yes | yes |
| 3 | f | 71 | IgG κ | other | 9.8 | CTx, RTx | yes | none |
| 4 | m | 51 | light chain κ | other | 3.1 | CTx, RTx | yes | none |
| 5 | f | 63 | light chain κ | other | 1.5 | CTx, RTx | yes | none |
| 6 | m | 52 | IgG κ | high risk | 4.8 | CTx, RTx | yes | yes |
| 7 | m | 54 | IgG κ | other | 6.8 | CTx, RTx | none | yes |
| 8 | m | 50 | IgA κ | other | 1.5 | CTx, RTx | yes | none |
| 9 | m | 75 | IgG λ | n/a | 3.1 | CTx | yes | none |
| 10 | f | 51 | IgA κ | other | 1.4 | CTx, RTx | yes | none |
| 11 | m | 72 | IgG κ | n/a | 3.1 | CTx | yes | none |
| 12 | m | 39 | IgG κ | n/a | 4.7 | CTx, RTx | yes | none |
| 13 | m | 44 | IgG κ | other | 11.1 | CTx, RTx | yes | none |
| 14 | m | 49 | IgA κ | high risk | 6.6 | CTx, RTx | yes | yes |
| 15 | m | 54 | IgA λ | high risk | 2.1 | CTx | yes | none |
| 16 | m | 67 | light chain κ | n/a | 6.5 | CTx | yes | yes |
| 17 | f | 59 | IgG κ | high risk | 4.8 | CTx, RTx | yes | yes |
| 18 | m | 50 | light chain κ | high risk | 1.5 | CTx, RTx | yes | none |
| 19 | m | 51 | IgG κ | other | 2.9 | CTx, RTx | yes | none |
| 20 | m | 64 | IgG λ | n/a | 7.5 | CTx | yes | yes |
| 21 | m | 55 | IgA λ | other | 2.5 | CTx, RTx | yes | none |
| 22 | m | 67 | IgG λ | n/a | 3.6 | CTx, RTx | yes | yes |
| 23 | m | 57 | IgG λ | other | 9.4 | CTx, RTx | yes | yes |
| 24 | m | 58 | IgG κ | other | 0.6 | CTx, RTx | yes | none |
| 25 | f | 64 | IgG λ | other | 4.0 | CTx, RTx | yes | yes |
| 26 | m | 49 | IgA λ | high risk | 4.7 | CTx | yes | yes |
| 27 | m | 63 | IgG λ | n/a | 0.4 | CTx, RTx | yes | none |
| 28 | m | 69 | IgG k | other | 3.2 | CTx, RTx | yes | none |
| 29 | m | 63 | IgA λ | high risk | 1.0 | CTx | yes | none |
| 30 | f | 72 | Ig G λ | n/a | 6.8 | CTx, RTx | yes | none |
| 31 | m | 72 | IgG k | n/a | 14.2 | CTx, RTx | yes | none |
| 32 | m | 53 | Ig A λ | n/a | 6.0 | CTx, RTx | yes | yes |
| 33 | m | 69 | IgG λ | other | 3.6 | CTx | yes | none |
| 34 | f | 65 | light chain κ | n/a | 5.2 | CTx, RTx | yes | none |
| 35 | m | 52 | IgG k | n/a | 2.8 | CTx, RTx | yes | yes |
| 36 | f | 75 | IgG λ | high risk | 0.6 | CTx | yes | none |
| 37 | m | 54 | IgG λ | n/a | 7.8 | CTx, RTx | none | yes |
High-risk cytogenetics included the presence of del(17p), t(4;14), t(14;16), t(14;20) and chromosome 1 abnormalities, whereas all other karyotypes were classified as standard risk. Disease duration is given in years. CTx = chemotherapy including novel agents, RTx = radiotherapy. Auto-Tx = autologous stem cell transplant, allo-Tx = allogeneic stem cell transplant. N/A = information not available.